Lilly announces clinical study to evaluate JAK inhibitors Olumiant and antiangitosin-2 mono-antilyialysis LY3127804 for treatment of new coronavirus COVID-19 patients
-
Last Update: 2020-05-29
-
Source: Internet
-
Author: User
Search more information of high quality chemicals, good prices and reliable suppliers, visit
www.echemi.com
Lilly announced that it has reached an agreement with the National Institute of Allergy and Infectious Diseases (NIAID) to begin testing Olumiant as a potential treatment for patients hospitalized with the new coronavirus COVID-19The study of the oral JAK1/JAK2 inhibitor for COVID-19 will be tested in the United States starting this month and data is expected to be available in the next two monthsthe company said it would also advance angiogenesis-2 (Ang2) monoantigen LY3127804 to Stage II clinical lying for patients with COVID-19 pneumonia, which is at higher risk of acute respiratory distress syndrome (ARDS)Lilly notes: 'Ang2 is known to rise in PATIENTs with ARDS'The study will look at the use of monoclonal antibodies to suppress Ang2 to see if it can reduce the progression of ARDS or the need for mechanical ventilationabout Olumiant, Lilly said the anti-inflammatory activity of the drug may help reduce inflammatory cascades in some COVID-19 patientsolumiant, developedLilly and Incyte, has been approved in the United States, Europe and Japan for the treatment of specific types of rheumatoid arthritis patientsEarlier this month, Incyte and partner Novartis announced a research program to conduct Phase III tests for JAK1/JAK2 inhibitor ruxolitinib to treat patients with COVID-19-related cytokine storms
This article is an English version of an article which is originally in the Chinese language on echemi.com and is provided for information purposes only.
This website makes no representation or warranty of any kind, either expressed or implied, as to the accuracy, completeness ownership or reliability of
the article or any translations thereof. If you have any concerns or complaints relating to the article, please send an email, providing a detailed
description of the concern or complaint, to
service@echemi.com. A staff member will contact you within 5 working days. Once verified, infringing content
will be removed immediately.
